How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

333,018 results for

cardio*

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Full Text available with Trip Pro

Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) . Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Factors facilitating implementation of interventions to reduce avoidable admissions for cardiovascular and respiratory conditions can be identified at a patient, general practitioner and health system level. {{author}} {{($index , & . Duncan Chambers * , Anna Cantrell, Andrew Booth School

2020 NIHR HTA programme

2. Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT Full Text available with Trip Pro

Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please (...) choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Enhanced motivational interviewing, in group or individual formats, did not reduce weight or increase physical activity in adults with high cardiovascular disease risk. {{author}} {{($index , , , , , , , , , , , , , , & . Khalida Ismail 1, * , Daniel Stahl 2 , Adam Bayley 1 , Katherine Twist 1 , Kurtis

2020 NIHR HTA programme

3. Promoting patient utilization of outpatient cardiac rehabilitation: ajoint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement

Cardiovascular Health and Rehabilitation Association, Brazilian Association of Cardiorespiratory and Intensive Care Physiotherapy, Brazilian Group of Cardiopulmonary and Metabolic Rehabilitation, British Association for Cardiovascular Prevention and Rehabilitation, Canadian Association of Cardiovascular Prevention and Rehabilitation, Canadian Cardiovascular Society, Canadian Council of Cardiovascular Nurses, Cardiac Health Foundation of Canada, Cardiac Society Brunei Darussalam, Indonesian Heart Association (...) Promoting patient utilization of outpatient cardiac rehabilitation: ajoint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement Promoting Patient Utilization of Outpatient Cardiac Rehabili... : Journal of Cardiopulmonary Rehabilitation and Prevention ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been

2020 CPG Infobase

4. Promoting patient utilization of outpatient cardiac rehabilitation: A joint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement Full Text available with Trip Pro

them to complete programs. Previous article in issue Next article in issue Keywords Coronary artery disease Secondary prevention Health services accessibility Disease management Cardiac rehabilitation Recommended articles Citing articles (0) Endorsed by: American Society for Preventive Cardiology, Association Francophone de Cardiologie Préventive, Australian Cardiovascular Health and Rehabilitation Association, Brazilian Association of Cardiorespiratory and Intensive Care Physiotherapy, Brazilian (...) Group of Cardiopulmonary and Metabolic Rehabilitation, British Association for Cardiovascular Prevention and Rehabilitation, Canadian Association of Cardiovascular Prevention and Rehabilitation, Canadian Cardiovascular Society, Canadian Council of Cardiovascular Nurses, Cardiac Health Foundation of Canada, Cardiac Society Brunei Darussalam, Indonesian Heart Association, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Physical and Rehabilitation

2020 CPG Infobase

5. Ezetimibe for the prevention of cardiovascular Events

Ezetimibe for the prevention of cardiovascular Events 1 Translation of the executive summary of the rapid report A18-83 Ezetimib zur Prävention kardiovaskulärer Ereignisse (Version 2.0; Status: 3 September 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A18-83 Ezetimibe for the prevention of cardiovascular events 1 (...) Extract of rapid report A18-83 Version 2.0 Ezetimibe for the prevention of cardiovascular events 3 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ezetimibe for the prevention of cardiovascular events Commissioning agency: Federal Joint Committee Commission awarded on: 22 November 2018 Internal Commission No.: A18-83 Address of publisher: Institut für Qualität und

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Reduction in saturated fat intake for cardiovascular disease. (Abstract)

Reduction in saturated fat intake for cardiovascular disease. Reducing saturated fat reduces serum cholesterol, but effects on other intermediate outcomes may be less clear. Additionally, it is unclear whether the energy from saturated fats eliminated from the diet are more helpfully replaced by polyunsaturated fats, monounsaturated fats, carbohydrate or protein.To assess the effect of reducing saturated fat intake and replacing it with carbohydrate (CHO), polyunsaturated (PUFA (...) ), monounsaturated fat (MUFA) and/or protein on mortality and cardiovascular morbidity, using all available randomised clinical trials.We updated our searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid) and Embase (Ovid) on 15 October 2019, and searched Clinicaltrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) on 17 October 2019.Included trials fulfilled the following criteria: 1) randomised; 2) intention to reduce saturated fat intake OR intention

2020 Cochrane

7. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. (Abstract)

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. This is the second update of the review first published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also (...) increase adverse events. The optimal blood pressure target in people with hypertension and established cardiovascular disease remains unknown.To determine if lower blood pressure targets (135/85 mmHg or less) are associated with reduction in mortality and morbidity as compared with standard blood pressure targets (140 to 160/90 to 100 mmHg or less) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive

2020 Cochrane

8. Reduction in saturated fat intake for cardiovascular disease. (Abstract)

Reduction in saturated fat intake for cardiovascular disease. Reducing saturated fat reduces serum cholesterol, but effects on other intermediate outcomes may be less clear. Additionally, it is unclear whether the energy from saturated fats eliminated from the diet are more helpfully replaced by polyunsaturated fats, monounsaturated fats, carbohydrate or protein.To assess the effect of reducing saturated fat intake and replacing it with carbohydrate (CHO), polyunsaturated (PUFA (...) ), monounsaturated fat (MUFA) and/or protein on mortality and cardiovascular morbidity, using all available randomised clinical trials.We updated our searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid) and Embase (Ovid) on 15 October 2019, and searched Clinicaltrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) on 17 October 2019.Included trials fulfilled the following criteria: 1) randomised; 2) intention to reduce saturated fat intake OR intention

2020 Cochrane

9. Mechanical assist devices for acute cardiogenic shock. (Abstract)

Mechanical assist devices for acute cardiogenic shock. Cardiogenic shock (CS) is a state of critical end-organ hypoperfusion due to a primary cardiac disorder. For people with refractory CS despite maximal vasopressors, inotropic support and intra-aortic balloon pump, mortality approaches 100%. Mechanical assist devices provide mechanical circulatory support (MCS) which has the ability to maintain vital organ perfusion, to unload the failing ventricle thus reduce intracardiac filling pressures (...) which reduces pulmonary congestion, myocardial wall stress and myocardial oxygen consumption. This has been hypothesised to allow time for myocardial recovery (bridge to recovery) or allow time to come to a decision as to whether the person is a candidate for a longer-term ventricular assist device (VAD) either as a bridge to heart transplantation or as a destination therapy with a long-term VAD.To assess whether mechanical assist devices improve survival in people with acute cardiogenic shock.We

2020 Cochrane

10. Chelation therapy for atherosclerotic cardiovascular disease. (Abstract)

Chelation therapy for atherosclerotic cardiovascular disease. Chelation therapy is promoted and practiced around the world as a form of alternative medicine in the treatment of atherosclerotic cardiovascular disease. It has been suggested as a safe, relatively inexpensive, non-surgical method of restoring blood flow in atherosclerotic vessels. However, there is currently limited high-quality, adequately-powered research informing evidence-based medicine on the topic, specifically regarding (...) clinical outcomes. Due to this limited evidence, the benefit of chelation therapy remains controversial at present. This is an update of a review first published in 2002.To assess the effects of ethylene diamine tetra-acetic acid (EDTA) chelation therapy versus placebo or no treatment on clinical outcomes among people with atherosclerotic cardiovascular disease.For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, Cochrane Central Register

2020 Cochrane

11. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death

Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death Subcutaneous implantable cardio Subcutaneous implantable cardiov verter erter defibrillator insertion for pre defibrillator insertion for prev venting sudden enting sudden cardiac death cardiac death Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg603 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) details about all patients having subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death onto a register by submitting data to the National Audit of Cardiac Rhythm Management database at the UK National Institute for Cardiovascular Outcomes Research (NICOR), and should review local clinical outcomes. 1.3 The procedure should only be done by clinicians with specific training on inserting the device. 2 2 Indications and current treatments Indications

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

12. Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Prescrire IN ENGLISH - Spotlight ''Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications'', 1 January 2020 {1} {1} {1} | | > > > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight In the January issue of Prescrire International - Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications FREE DOWNLOAD In the "Reviews" section this month: what is dapagliflozin's harm-benefit balance in type 2 diabetes, in light of the results of a recent randomised, double-blind trial studying the drug's effect on cardiovascular outcomes? Full text available for free download. Summary A randomised, double-blind trial of dapagliflozin

2020 Prescrire

13. Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Societies Full Text available with Trip Pro

Journal of Cardiology. 2020; ( March 24th ) , Shah PB, Welt FGP, Mahmud E, et al. Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement. JACC Cardiovasc Interv. 2020. , Kirkpatrick J.N. Mitchell C. Taub C. Kort S. Hung J. Swaminathan M. ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak. J Am Coll Cardiol. 2020 (...) . J Am Coll Cardiol. 2020; Choi A.D. Abbara S. Branch K.R. et al. Society of Cardiovascular Computed Tomography Guidance for Use of Cardiac Computed Tomography Amidst the COVID-19 Pandemic. J Cardiovasc Comput Tomogr. 2020; ( Mar 21 (e-published ahead of print) ) : 2020 Haft J.W. Atluri P. Alawadi G. et al. Adult cardiac surgery during the COVID-19 Pandemic: A Tiered Patient Triage Guidance Statement. J Thorac Cardiovasc Surg. 2020 Apr 16; (e-published ahead of print) Hassan A. Arora R.C. Adams C

2020 Covid-19 Ad hoc guidelines

14. Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death

Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death Published March 2020 Volume 20, Number 3 ONTARIO HEALTH TECHNOLOGY ASSESSMENT SERIES Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment KEY MESSAGES What Is This Health Technology Assessment About? Heart failure is a condition in which the heart’s ability to pump enough blood to meet the body’s needs is reduced. Heart failure can occur (...) cardiocirculatory death (when the heart has stopped beating and there is no longer blood flow or a pulse). We looked at the budget impact of publicly funding this system for adult heart transplant recipients in Ontario. We also looked at the experiences, preferences, and values of people waiting for a heart transplant, people who had received a heart transplant, and family members of organ donors. What Did This Health Technology Assessment Find? Outcomes for people who received hearts donated after

2020 Health Quality Ontario

15. Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT Full Text available with Trip Pro

Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This research programme developed new ways of predicting cardiovascular disease risk for people with severe mental illnesses, but an evidence-based practitioner-led intervention in primary care did not reduce cholesterol more than treatment as usual. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . David

2019 NIHR HTA programme

16. A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study Full Text available with Trip Pro

A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry (...) , , , , , , , , , , & . Jessica M Harris 1 , Rachel C Brierley 1 , Maria Pufulete 1 , Chiara Bucciarelli-Ducci 2 , Elizabeth A Stokes 3 , John P Greenwood 4 , Stephen H Dorman 2 , Richard A Anderson 5 , Chris A Rogers 1 , Sarah Wordsworth 3 , Sunita Berry 6 , Barnaby C Reeves 1, * 1 Clinical Trials and Evaluation Unit, Bristol Trials Centre, University of Bristol, Bristol, UK 2 National Institute for Health Research (NIHR) Bristol Cardiovascular Research Unit, Bristol Heart Institute, University of Bristol, Bristol, UK 3

2019 NIHR HTA programme

17. Cardiovascular disease prevention: applying All Our Health

Cardiovascular disease prevention: applying All Our Health Cardiovascular disease prevention: applying All Our Health - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cardiovascular disease prevention: applying All Our Health Evidence and guidance to help healthcare (...) professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health. Published 9 January 2019 Last updated 16 December 2019 — From: Documents HTML Details This resource helps: front-line health professionals team leaders or managers senior or strategic leaders to prevent ill health and promote wellbeing as part of their everyday practice. We also recommend important actions that managers and staff holding strategic roles can take. View the full range of topics. Published 9

2020 Public Health England

18. 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease Full Text available with Trip Pro

DBP Diastolic blood pressure DCM Dilated cardiomyopathy EACPR European Association for Cardiovascular Prevention and Rehabilitation EAPC European Association of Preventive Cardiology ECV Extracellular volume ECG Electrocardiogram EDS Ehlers Danlos syndrome EF Ejection fraction EP Electrophysiological ESC European Society of Cardiology Ex-R Exercise-related exCR Exercise-based cardiac rehabilitation FFR Fractional flow reserve FITT Frequency, intensity, time, and type HCM Hypertrophic (...) 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease | European Heart Journal | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Navbar Search Filter Mobile Microsite Search Term search filter search input Article

2020 European Society of Cardiology

19. Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Prescrire IN ENGLISH - Spotlight '' Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality'', 1 May 2020 {1} {1} {1} | | > > > Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) |   |   |   |   |   |   |   |  Spotlight In the May issue of Prescrire International: Dulaglutide (Trulicity°) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality FREE DOWNLOAD In patients with type 2 diabetes who had a modest elevation of HbA1c, a recent trial suggested that addition of dulaglutide to hypoglycaemic therapy slightly reduced the risk of stroke, but did not reduce either all-cause mortality

2020 Prescrire

20. Tafamidis meglumine (Vyndaqel) - for the treatment of adult patients with cardiomyopathy due to transthyretin?mediated amyloidosis

Tafamidis meglumine (Vyndaqel) - for the treatment of adult patients with cardiomyopathy due to transthyretin?mediated amyloidosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product

2020 Health Canada - Drug and Health Product Register

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>